Foreign Aid Cuts Will Lead to 34,000 More Pregnancy-Related Deaths in Just One Year 

The freeze on U.S. foreign assistance funding and the subsequent stop work order has already taken an irreversible toll on global health programs, including family planning services, causing chaos across public health systems and forcing many sexual and reproductive health providers and programs to close doors permanently. Despite ongoing litigation to challenge these actions in court—including an important court victory that found this attack likely unconstitutional—most USAID partners are still waiting for government payments for work already completed. Adding to the upheaval, the administration gutted USAID staff and cancelled 83 percent of its aid contracts. 

Contrary to the Trump administration’s claims, cutting foreign aid for reproductive health is not a fiscal gain, but a significant step backward.  

How Project 2025 Seeks to Obliterate Sexual and Reproductive Health and Rights

Project 2025 promotes a presidential agenda that rolls back civil and human rights and implements extremist conservative policies across every federal department and agency. Its sweeping far-right policy framework, by the conservative think tank the Heritage Foundation, includes numerous attacks on sexual and reproductive health and rights. 

This fact sheet enumerates some of the agenda’s most serious threats to sexual and reproductive health and describes potential effects.

As Abortion Returns to the Supreme Court, It’s Critical to See the Bigger Picture

While the Dobbs decision to overturn Roe v. Wade one year ago was a shock to our system, we must recognize that overturning Roe is not the anti-abortion movement’s end goal—it is to upend sexual and reproductive rights and freedom for millions of people. And number one on their list of priorities is banning abortion across the country, at any point in pregnancy.

Like other restrictions on reproductive healthcare, the harm that will be done if the Supreme Court decides to overrule the authority of the FDA and to further restrict access to mifepristone cannot be overstated.